Ablynx signs deal with Chinese pharmaceutical market leader

Summary

Flemish pharmaceutical firm Ablynx will provide the anti-inflammatory ozoralizumab to China’s Eddingpharm

Ghent company to provide ozoralizumab

Ghent drug company Ablynx has expanded its co-operation with Eddingpharm, one of China’s leading pharmaceutical companies. Eddingpharm will be responsible for the clinical development, registration and commercialisation on the Chinese market of the anti-inflammatory agent ozoralizumab. Ablynx will receive up to 20% of annual net sales.

Ablynx was founded in 2001 as a spin-off of the Flemish Institute for Biotechnology (VIB). The firm discovered and developed Nanobodies™, a novel class of therapeutic proteins based on so-called single-domain antibody fragments. These antibody fragments were first detected by VIB scientists in the blood of camels. Camels and llamas are still used in Ablynx’s production facilities.

Nanobodies can help against a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Ablynx has six Nanobodies in clinical development, one of which is ozoralizumab. This Nanobody has proven to be a very affective anti-inflammatory agent, which could be used in treatment of arthritis and Crohn’s disease.

China’s pharmaceutical market is expected to grow in the coming year by nearly 19% a year. It’s expected to rank number two in the world in 2016, just one place behind the United States.

Flemish pharmaceutical firm Ablynx will provide the anti-inflammatory ozoralizumab to China’s Eddingpharm.

LinkedIn this